A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With
A phase 3 trial of Sacituzumab tirumotecan, Pemetrexed, Tisotumab vedotin in cervical cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) is a phase 3 interventional study registered as NCT06459180 by Merck Sharp & Dohme LLC, with 686 participants planned, started 2024-07-24 and due to reach its primary completion in 2028-06-15. Interventions recorded: Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Shares Sacituzumab tirumotecan, Pemetrexed, Gemcitabine, Merck & Co. (MSD).
- TrialA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm
Shares Sacituzumab tirumotecan, Pemetrexed, Gemcitabine, Merck & Co. (MSD).
- TrialSacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With
Shares Sacituzumab tirumotecan, Pemetrexed, Merck & Co. (MSD).
- TrialA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Shares Sacituzumab tirumotecan, Gemcitabine, Merck & Co. (MSD).
- TrialSacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A
Shares Sacituzumab tirumotecan, Pemetrexed, Merck & Co. (MSD).
- TrialStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [
Shares Vinorelbine, Pemetrexed, Gemcitabine.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Cervical cancer.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Pemetrexed, Gemcitabine, Merck & Co. (MSD).